Titan Pharmaceuticals, Inc.
Long
Aggiornato

TTNP 1D Close Up w/bars pattern

384
test
$31.19 Gap Close
Titan Pharmaceuticals, Inc. engages in development of therapeutics for the treatment of chronic diseases utilizing its long-term, continuous drug delivery platform, ProNeura. Its lead product is Probuphine, a buprenorphine implant for the maintenance treatment of opioid addiction. The company was founded by Louis R. Bucalo in February 7, 1992 and is headquartered in South San Francisco, CA.
Nota
$2.00-$2.01 entry point
Nota
TTNP 1W +1000%
Nota
Bottom entry $1.25

Declinazione di responsabilità

Le informazioni ed i contenuti pubblicati non costituiscono in alcun modo una sollecitazione ad investire o ad operare nei mercati finanziari. Non sono inoltre fornite o supportate da TradingView. Maggiori dettagli nelle Condizioni d'uso.